Xv Yingjie, Wei Zongjie, Lv Fajin, Jiang Qing, Guo Haoming, Zheng Yineng, Zhang Xuan, Xiao Mingzhao
Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Quant Imaging Med Surg. 2024 Oct 1;14(10):7031-7045. doi: 10.21037/qims-24-35. Epub 2024 Sep 12.
The preoperative prediction of the pathological nuclear grade of clear cell renal cell carcinoma (CCRCC) is crucial for clinical decision making. However, radiomics features from one or two computed tomography (CT) phases are required to predict the CCRCC grade, which reduces the predictive performance and generalizability of this method. We aimed to develop and externally validate a multiparameter CT radiomics-based model for predicting the World Health Organization/International Society of Urological Pathology (WHO/ISUP) grade of CCRCC.
A total of 500 CCRCC patients at The First, Second, and Yongchuan Hospitals of Chongqing Medical University between January 2016 and May 2022 were retrospectively enrolled in this study. The patients were divided into the training set (n=268), internal testing set (n=115), and two external testing sets (testing set 1, n=62; testing set 2, n=55). Radiomics features were extracted from multi-phase CT images, and radiomics signatures (RSs) were created by least absolute shrinkage and selection operator (LASSO) regression. In addition, a clinical model was developed. A combined model was also established that integrated the RSs with the clinical factors, and was visualized via a nomogram. The performance of the established model was assessed using area under the curve (AUC) values, a calibration curve analysis, and a decision curve analysis (DCA).
Among the four RSs and the clinical model, the RS-Triphasic had the best predictive performance with AUCs of 0.88 [95% confidence interval (CI): 0.85-0.91] and 0.84 (95% CI: 0.74-0.95) in the training and testing sets, respectively, and 0.82 (95% CI: 0.72-0.93) and 0.82 (95% CI: 0.71-0.93) in external testing sets 1 and 2. Integrating the RS-Triphasic, RS-corticomedullary phase (CMP), RS-nephrographic phase (NP), RS-non-contrast phase (NCP) with the clinical risk factors, a combined model was established with AUCs of 0.92 (95% CI: 0.89-0.94), 0.86 (95% CI: 0.76-0.95), 0.84 (95% CI: 0.73-0.95), and 0.82 (95% CI: 0.70-0.94) for the training, internal testing, and external testing sets 1 and 2, respectively. The DCA indicated that the nomogram had a greater overall net benefit than the clinical and radiomics models.
The multiparameter CT RS fusion-based model had high accuracy in differentiating between high- and low-grade CCRCC preoperatively. Thus, it has great potential as a useful tool for personalized treatment planning and clinical decision making for CCRCC patients.
术前预测透明细胞肾细胞癌(CCRCC)的病理核分级对于临床决策至关重要。然而,预测CCRCC分级需要一两个计算机断层扫描(CT)期相的影像组学特征,这降低了该方法的预测性能和通用性。我们旨在开发并外部验证一种基于多参数CT影像组学的模型,用于预测世界卫生组织/国际泌尿病理学会(WHO/ISUP)的CCRCC分级。
回顾性纳入2016年1月至2022年5月在重庆医科大学附属第一、第二和永川医院的500例CCRCC患者。患者被分为训练集(n = 268)、内部测试集(n = 115)和两个外部测试集(测试集1,n = 62;测试集2,n = 55)。从多期CT图像中提取影像组学特征,并通过最小绝对收缩和选择算子(LASSO)回归创建影像组学特征(RS)。此外,还开发了一个临床模型。还建立了一个将RS与临床因素相结合的联合模型,并通过列线图进行可视化。使用曲线下面积(AUC)值、校准曲线分析和决策曲线分析(DCA)评估所建立模型的性能。
在四个RS和临床模型中,RS-三相在训练集和测试集中的预测性能最佳,AUC分别为0.88[95%置信区间(CI):0.85 - 0.91]和0.84(95%CI:0.74 - 0.95),在外部测试集1和2中的AUC分别为0.82(95%CI:0.72 - 0.93)和0.82(95%CI:0.71 - 0.93)。将RS-三相、RS-皮质髓质期(CMP)、RS-肾实质期(NP)、RS-平扫期(NCP)与临床危险因素相结合,建立了一个联合模型,训练集、内部测试集和外部测试集1和2的AUC分别为0.92(95%CI:0.89 - 0.94)、0.86(95%CI:0.76 - 0.95)、0.84(95%CI:0.73 - 0.95)和0.82(95%CI:0.70 - 0.94)。DCA表明列线图的总体净效益高于临床和影像组学模型。
基于多参数CT RS融合的模型在术前区分高、低级别CCRCC方面具有较高的准确性。因此,它作为CCRCC患者个性化治疗规划和临床决策的有用工具具有巨大潜力。